» Articles » PMID: 28611770

Relevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance

Overview
Journal Front Immunol
Date 2017 Jun 15
PMID 28611770
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The CD6 lymphocyte receptor has been involved in the pathophysiology of different autoimmune disorders and is now considered a feasible target for their treatment. data show the relevance of CD6 in the stabilization of adhesive contacts between T-cell and antigen-presenting cells, and the modulation of T-cell receptor signals. However, the consequences of such a function are yet undisclosed due to the lack of suitable genetically modified animal models. Here, the and challenge of CD6-deficient (CD6) cells with allogeneic cells was used as an approach to explore the role of CD6 in immune responses under relative physiological stimulatory conditions. Mixed lymphocyte reaction (MLR) assays showed lower proliferative responses of splenocytes from CD6 mice together with higher induction of regulatory T cells (T, CD4CD25FoxP3) with low suppressive activity on T and B-cell proliferation. In line with these results, CD6 mice undergoing a lupus-like disorder induced by chronic graft-versus-host disease (cGvHD) showed higher serum titers of anti-double-stranded DNA and nucleosome autoantibodies. This occurred together with reduced splenomegaly, which was associated with lower bromodesoxyuridine incorporation of spleen cells and with increased percentages of spleen follicular B cells (B2, CD21CD23) and T cells. Interestingly, functional analysis of generated CD6 T cells exhibited defective suppressive activity. In conclusion, the data from MLR and cGvHD-induced lupus-like models in CD6 mice illustrate the relevance of CD6 in T (and B) cell proliferative responses and, even more importantly, T induction and suppressive function in the maintenance of peripheral tolerance.

Citing Articles

Beyond FOXP3: a 20-year journey unravelling human regulatory T-cell heterogeneity.

Santosh Nirmala S, Kayani K, Gliwinski M, Hu Y, Iwaszkiewicz-Grzes D, Piotrowska-Mieczkowska M Front Immunol. 2024; 14:1321228.

PMID: 38283365 PMC: 10811018. DOI: 10.3389/fimmu.2023.1321228.


CD6 and Its Interacting Partners: Newcomers to the Block of Cancer Immunotherapies.

Aragon-Serrano L, Carrillo-Serradell L, Planells-Romeo V, Isamat M, Velasco-de Andres M, Lozano F Int J Mol Sci. 2023; 24(24).

PMID: 38139340 PMC: 10743954. DOI: 10.3390/ijms242417510.


Experimental and genetic evidence for the impact of and expression and variation in inflammatory bowel disease.

Casado-Llombart S, Velasco-de Andres M, Catala C, Leyton-Pereira A, Gutierrez-Cozar R, Suarez B Front Immunol. 2022; 13:966184.

PMID: 36211446 PMC: 9532939. DOI: 10.3389/fimmu.2022.966184.


CD6 deficiency impairs early immune response to bacterial sepsis.

Catala C, Velasco-de Andres M, Leyton-Pereira A, Casado-Llombart S, Saez Moya M, Gutierrez-Cozar R iScience. 2022; 25(10):105078.

PMID: 36157587 PMC: 9490029. DOI: 10.1016/j.isci.2022.105078.


Soluble CD5 and CD6: Lymphocytic Class I Scavenger Receptors as Immunotherapeutic Agents.

Velasco-de Andres M, Casado-Llombart S, Catala C, Leyton-Pereira A, Lozano F, Aranda F Cells. 2020; 9(12).

PMID: 33287301 PMC: 7761703. DOI: 10.3390/cells9122589.


References
1.
Zhao C, Shi G, Vistica B, Hinshaw S, Wandu W, Tan C . Induced regulatory T-cells (iTregs) generated by activation with anti-CD3/CD28 antibodies differ from those generated by the physiological-like activation with antigen/APC. Cell Immunol. 2014; 290(2):179-84. DOI: 10.1016/j.cellimm.2014.06.004. View

2.
Kamoun M, Kadin M, Martin P, Nettleton J, Hansen J . A novel human T cell antigen preferentially expressed on mature T cells and shared by both well and poorly differentiated B cell leukemias and lymphomas. J Immunol. 1981; 127(3):987-91. View

3.
Krupashankar D, Dogra S, Kura M, Saraswat A, Budamakuntla L, Sumathy T . Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. J Am Acad Dermatol. 2014; 71(3):484-92. DOI: 10.1016/j.jaad.2014.01.897. View

4.
Gimferrer I, Ibanez A, Farnos M, Sarrias M, Fenutria R, Rosello S . The lymphocyte receptor CD6 interacts with syntenin-1, a scaffolding protein containing PDZ domains. J Immunol. 2005; 175(3):1406-14. DOI: 10.4049/jimmunol.175.3.1406. View

5.
Gimferrer I, Calvo M, Mittelbrunn M, Farnos M, Sarrias M, Enrich C . Relevance of CD6-mediated interactions in T cell activation and proliferation. J Immunol. 2004; 173(4):2262-70. DOI: 10.4049/jimmunol.173.4.2262. View